> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Verrica Asks FDA to End Ycanth Compounding
- URL: https://www.fdaweb.com/verrica-asks-fda-to-end-ycanth-compounding/
- Published: 2023-10-17T12:00:00.000Z
- Updated: 2026-09-14T14:13:30.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155584

Verrica Pharmaceuticals is asking FDA to take specific actions on the compounding of its Ycanth (cantharidin) by pharmacies and outsourcing facilities. Ycanth is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The [petition](https://downloads.regulations.gov/FDA-2023-P-4510-0001/attachment%5F1.pdf?ref=fdaweb.com) asks the agency to:

- remove cantharidin from the list of bulk drug substances that can be used in compounding;
- remove cantharidin from the Section 503B category 1 or rescind the 503B interim policy completely; and
- issue a final *Federal Register* notice not to include cantharidin on the list of bulk drug substances that outsourcing facilities can use in compounding under Section 503B of the Federal Food, Drug, and Cosmetic Act.

The petition says that with the approval of Ycanth, there is no clinical need for compounders to formulate cantharidin. “In fact,” it says, “the continued compounding of cantharidin, especially without a proven clinical need, unnecessarily exposes patients to the risks of unapproved and potentially unsafe cantharidin products and, moreover, effectively subverts and undermines the entire drug approval process.”